Study identifies epigenetic patterns affecting insulin and glucagon production in type 2 diabetes
Researchers at Lund University in Sweden have carried out the most detailed mapping to date of the epigenome…
Eli Lilly’s Retatrutide Shows Strong Weight Loss, Nears Diabetes Approval
Retatrutide’s Triple Action Targets Metabolism Eli Lilly’s retatrutide drug is making waves in the metabolic health field. It…
GLP-1 drugs cut heart and kidney risks in type 1 diabetes study
A major real-world analysis suggests GLP-1 receptor agonists could offer heart, kidney, and weight benefits in type 1…
Patients who stop GLP-1 drugs often restart or try alternatives
A large real-world study shows that patients who stop popular GLP-1–based weight-loss drugs often return to treatment or…
How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?
A sweeping Lancet review reveals how modern incretin-based drugs are reshaping treatment for obesity and diabetes, delivering powerful…
How GLP-1 drugs affect the body beyond weight loss and glucose control
Widely used weight-loss and diabetes drugs show clear benefits, but emerging evidence clarifies their side effects, rare risks,…
Users prioritize weight loss despite side effects
An examination of user reviews finds that people continue off-label Ozempic when it delivers results, even if side…
Improving survival in people with severe psychiatric disorders
An expert editorial suggests that widely used diabetes and obesity drugs may help close the long-standing mortality gap…
Swapping high-carb snacks for tree nuts cuts food cravings in young adults at metabolic risk
Swapping common snack foods for a modest daily portion of tree nuts curbed cravings for sweets and fast…
Searches for “Ozempic face” surge as people look for filler-based solutions
New search data reveal that as interest in “Ozempic face” surges, people increasingly turn to nonsurgical fillers rather…
Study compares GLP-1 drug benefits and finds substantial variation in clinical effects
A new umbrella review reveals how GLP-1 therapies shape cardiovascular, renal, and metabolic outcomes in type 2 diabetes…
Diabetes remission possible with GLP-1 drugs, Italian study confirms
Real-world data from over 14,000 Italian adults reveal that GLP-1 receptor agonists can induce remission in type 2…